
Appointments and Honors
Medical Director of UW Health Eye Clinic – Rockford
Subspecialty
Retina, macula and vitreous diseases
Medical and Surgical Interests
- Age-related macular degeneration
- Diabetic retinopathy
- Medical retina disease
- Retinal vascular disease
Research Interests
- Vitreoretinal clinical trials
Research Highlights
Dr. Gottlieb contributed to the clinical data of a formative study published in the New England Journal of Medicine that found that the anti-VEGF inhibitors, aflibercept, bevacizumab, or ranibizumab improved visual acuity for those that suffer from diabetic macular edema. Interestingly, when participants had worse visual acuity at baseline, alibercept was more effective in improving vision. The study was conducted through the Diabetic Retinopathy Clinical Research Network and included more than 89 clinical sites. The outcomes have far-reaching implications for clinical treatment of macular edema and have been cited over 600 times to date.
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema
Education
Fellowships: Surgical Retina, Wills Eye Hospital, Philadelphia, PA; Medical Retina, Bascom Palmer Eye Institute, Miami, FL
Residency: University of Michigan Kellogg Eye Center, Ann Arbor, MI
Internship: Pacific Presbyterian Medical Center, San Francisco, CA
Medical School: Duke University School of Medicine, Durham, NC